ABSTRACT: In December 2014, the legal blood alcohol limit for drivers in both Scotland and New Zealand was reduced from 80 to 50 mg/100 mL. This paper reports a retrospective study comparing changes in the toxicological findings in deceased drivers and motorcyclists before and after the limit change in both jurisdictions. A year of fatal motor vehicle crashes prior to and following the limit change is examined for both countries. In Scotland, there was an increase in drug prevalence among fatally injured drivers and motorcyclists, with the use of all drug groups increasing after the limit change, with the exception of cannabinoids. In New Zealand, there was a reduction in cases involving drugs only, but increases in the numbers of deceased drivers and motorcyclists positive for alcohol only and co-using alcohol and drugs.
The role of alcohol as a major factor in motor vehicle crashes (MVCs) has been firmly established (1) . Driving is a complex task, requiring the co-operation of several different cognitive and psychomotor functions at once (2) (psychomotor capability, physical space awareness, reaction times, etc. (3)), and drivers may be significantly impaired by the use of alcohol (4) and/or other psychoactive substances (5) .
The Long Beach/Fort Lauderdale study demonstrated a relative crash risk due to alcohol showing a dose-response relationship beginning at blood alcohol concentrations (BACs) of 40-50 mg/100 mL and increasing exponentially at BACs of 100 mg/100 mL or greater (1) . Driving skills are significantly impaired at BACs in the 50-80 mg/100 mL range (6) , and even, BACs as low as 20 mg/100 mL can affect driver performance by slowing reaction times (7) .
The first country to introduce a legal per se BAC limit was Norway, in 1936 (8). The limit was set at 50 mg/100 mL and has since been reduced to 20 mg/100 mL (9) . Sweden reduced their legal BAC limit from 80 to 50 mg/100 mL in 1957 (10, 11) , and this has been followed by the same reduction in numerous other countries (12) . Worldwide, legal BAC limits now range from 20 to 150 mg/100 mL with some countries adopting a zero-tolerance approach (13).
The effectiveness of BAC limit reduction laws has been investigated in recent years by several researchers, using different evaluation methods and analysis procedures (14) . The most common method is to use official statistics, that is, numbers of arrests, collisions, and fatalities (15) . Using these official statistics, and different study designs, researchers have been able to draw conclusions about the effects of various legislative interventions on alcoholimpaired driving (7) , across a range of jurisdictions (11) . These include Australia (6, 16, 17) , Austria (18) , Brazil (19) , Denmark (20) , Hong Kong (21), Japan (22) , Norway (23) , Sweden (24) , and the U.S.A. (14, 25) , with the majority of studies appearing to show reductions in alcohol-related collisions, injuries, and/or fatalities (15) . However, the effectiveness measures and the analysis procedures have varied from study to study (11) , with researchers often relying on proxy measures of alcohol involvement (7) such as nighttime crashes compared to daytime crashes (11) rather than on measured BACs. Previous evaluation studies where BACs have been measured have also focussed solely on alcohol findings, without considering the use of drugs by drivers. It is important to take into account drug findings, as drug use by drivers is increasing (26) , accompanied by a widespread belief that drug driving is acceptable (27) and that crash risk is not significantly increased by drug use (28) . Moreover, a possible consequence of reinforcing anti-drink-drive messages with this kind of legislative intervention is a difference in the perceived or real risk of being apprehended by the police when driving under the influence of drugs (29) compared to alcohol. This may result in a change in the number of fatal MVCs where drivers are positive for drugs. For instance, in a study undertaken in Norway before (1989) (1990) ) and after (2001) (2002) , the reduction in BAC limit from 50 to 20 mg/100 mL, the proportion of fatally injured drivers positive for drugs and alcohol increased from 12.4% to 22.8%. During the same period, the proportion of fatally injured drivers positive for alcohol alone dropped from 32.9% to 23.9% (30) .
On 1 December 2014, the legal BAC limit was reduced in New Zealand from 80 to 50 mg/100 mL by means of the Land Transport Amendment Act (no 2) 2014. On 5 December 2014, the same reduction in BAC limit was introduced in Scotland via the Road Traffic Act 1988 (Prescribed Limit) (Scotland) Regulations 2014. Both countries ran high-profile media campaigns informing members of the public about the change (31,32). In New Zealand, the new limit applies to drivers aged 20 and over; there is now a zero-tolerance approach to drink-driving for drivers under 20 years of age. Drug-driving legislation in Scotland is governed by section 4 of the Road Traffic Act 1988 and is an impairment offence, with no statutory defense for the use of prescription medications by an impaired driver. In New Zealand, section 11A of the Land Transport Act 1998 sets out a zero-tolerance offence of driving while impaired with evidence of a qualifying drug in the blood. The Act includes a defense for drivers who can prove that they were using a qualifying drug in accordance with a current prescription and following the instructions of a health care professional.
In this paper, we compare changes in the toxicological findings in fatally injured drivers and motorcyclists from Scotland and New Zealand before and after the introduction of the new BAC limits. These two jurisdictions represent an interesting comparison for this type of study, as both countries have similar populations (33,34) and cultures, but different drug and alcohol use patterns (35,36). As the change in legislation happened in both countries at the same time, this study should avoid confounding factors such as broad social changes in alcohol use and driving behavior, which may have occurred during this period (15) . To minimize potential biases resulting from variations in roadside testing policies, for example, increased use of checkpoints or random breath testing, screening only alcohol-negative drivers for drugs (37) , and administrative differences, this study focusses on fatally injured drivers and motorcyclists (25) . Another reason that fatal MVCs were examined rather than nonfatal MVCs is because the declared impetus behind both countries' campaigns was to reduce road deaths (38, 39) .
To the authors' knowledge, this is the first study to examine the overall toxicological findings in driver fatalities before and after a BAC limit change, including drug findings. The change in legislation at the same time represents a rare opportunity to compare changes in the toxicological findings around the lowering of a BAC limit across two jurisdictions. Although comparisons of alcohol-and drug-impaired driving among countries can be complicated by differing methods in each country of measuring and reporting (30) , this study examines data resulting from two very similar MVC-investigation strategies. Fatal driver and motorcyclist MVC cases received by both laboratories between December 2013 and December 2015 were selected for this study (covering the 12-month periods before and after the BAC limits changed). Deceased cyclists, pedestrians, and passengers were not included. In Scotland, blood samples were initially analyzed for alcohol by headspace gas chromatography with flame ionization detection (GC-FID) and screened for a panel of eight drug groups by enzyme-linked immunosorbent assay (ELISA). Any drug groups presumptively positive following ELISA were confirmed by solid-phase extraction (CLEAN SCREEN â DAU cartridges) followed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). All cases included in this study were also analyzed for paracetamol by high-pressure liquid chromatography (HPLC) and for basic drugs by GC-MS, as described previously (40) .
Methods
In New Zealand, solid-phase extraction (TOXI-TUBES â ) followed by a liquid chromatography-time-of-flight-mass spectrometry (LC-TOF-MS) screen was carried out, which can detect 180 drugs of abuse and medications. This was combined with an ELISA screen for cannabinoids, positive results from which were verified by LC-MS/MS. More details on the analytical methods used are given in Table S1 of the Supplementary Information.
Most samples analyzed were postmortem blood, with antemortem hospital samples analyzed in five cases from Scotland and nine cases from New Zealand. Analysis was carried out in both countries as part of routine casework. Details of the postmortem interval in each case were not routinely collected. The laboratories also do not routinely receive information on crash culpability as part of death investigations. It should also be noted that not all fatal MVCs result in an autopsy; the decision to request an autopsy varies between police/Coronial areas and is influenced by the individual case circumstances as well as economic considerations (41) .
Similarly, only cases where full toxicological analyses were completed were included in the scope; cases where the submitting authority requested only alcohol or only certain types of drugs (e.g., drugs of abuse only or prescription drugs only) were removed. In Scotland, there were 106 driver and motorcyclist fatalities identified from the in-house database. In 17 cases (16.0%), no or limited toxicological analysis was requested, leaving a total of 89 cases within the scope of the study: 38 occurred before the BAC limit change and 51 occurred afterward.
In New Zealand, 326 driver and motorcyclist fatalities were identified. In 57 cases (17.5%), limited toxicological analysis was requested, leaving a total of 275 cases within the scope of the study: 129 occurred before the BAC limit change and 146 occurred afterward.
Results & Discussion
Geographical Area Figure 1 shows the regions of Scotland and New Zealand where the MVCs reported in this study took place over both years. There were small changes in the distribution of crashes among the geographical regions between the 2 years (2013-14 and 2014-15), and not all regions of Scotland were represented. In addition, some regions of Scotland reported fatal MVCs in 1 year, but not in the other. However, the regions in both countries with the highest number of crashes (Edinburgh and the Bay of Plenty) remained the same throughout the study. Interestingly, neither area represents the most populous region of either country. However, the New Zealand Transport Agency (NZTA) reports that people living in the Bay of Plenty were least likely to recognize the risk of drink-driving (42).
Summary
A summary of the cases identified in this study is shown in Table 1 . According to the table, in both countries, there was an apparent increase in the number of fatal MVCs after the BAC limit change. However, official statistics ( Fig. 2 ) demonstrate that while there was an increase in overall road traffic fatalities in New Zealand from 2014 to 2015, a decrease was observed in Scotland. Therefore, it appears that in New Zealand, the number of fatal MVCs was not reduced by a change in the legal BAC limit. It is unclear what other factors may have caused the increase in road traffic fatalities in New Zealand, but they may include increased numbers of drivers and distances being driven, changes in the use of seatbelts or mobile phones, and speeding.
It should be noted that although in most jurisdictions evidence for a positive impact on road safety, such as a reduction in fatal MVCs, is observed when legal BAC limits are lowered, this has not always been the case (15) . Figure 2 shows numbers of overall road traffic fatalities including pedestrians, cyclists, and passengers for both countries, whereas Table 1 reports driver fatalities only.
According to Table 1 , the number of cases in all categories increased in New Zealand, over the 2-year period, except drugsonly MVCs, where a decrease from 56 to 48 cases was (41) *In Scotland, a sample was deemed positive for alcohol at BAC ≥10 mg/100 mL. In New Zealand, a sample was deemed positive for alcohol at BAC ≥6 mg/100 mL. observed. In Scotland, there were small changes in the numbers of MVCs across each category, with the number of drugs-only MVCs doubling from 10 to 21 over the period studied.
Age and Gender
The ages and genders of the deceased drivers and motorcyclists in this study are shown in Table 2 . Consistent with previous studies, the majority of fatalities were male. Figure 3 shows the breakdown of vehicle types in this study. As can be seen from the figure, car drivers made up the majority of fatalities in both countries, followed by motorcyclists and other vehicle types. MVCs involving quad bikes and tractors were only included in this study if they occurred on a public road. There were only small changes in the percentages of drivers, motorcyclists, and other vehicle drivers across the 2-year period in both countries.
Vehicle Type

Alcohol
A summary of the BAC results from this study is shown in Table 3 . Eighteen of the 93 BACs measured in this study were <30 mg/100 mL (N = 16, New Zealand and N = 2, Scotland), and therefore, we cannot exclude the possibility that some of the alcohol detected was a result of postmortem bacterial production (43) . In Scotland, a sample was deemed positive for alcohol at BAC ≥10 mg/100 mL. In New Zealand, a sample was deemed positive for alcohol at BAC ≥6 mg/100 mL. In some cases, BACs between the analytical cutoffs for the two methods were observed: eight of the BACs for New Zealand fell between 6 and 10 mg/100 mL. These BACs are included in the dataset without modification. No subtractions from the BACs for analytical uncertainty (a practice known as "guard banding" (44)) were made in either jurisdiction.
Two-tailed t-tests conducted in MS Excel demonstrated that the differences between the mean BACs before and after the limit change for both countries were not significant. Table 3 shows that the percentage of total fatal MVC cases where the driver or motorcyclist was over the relevant BAC limit increased in both countries following the change, with a more pronounced increase noted in New Zealand. This is consistent with the previous observation that the lowering of a BAC limit to 50 mg/ 100 mL increases the proportion of drivers over the limit (30) .
In addition, in a study following trends in fatal MVCs around the reduction in BAC limit in Denmark from 80 to 50 mg/ 100 mL, the proportion of fatalities where the driver had a BAC ≥50 mg/100 mL was higher in the year after the limit change than in the preceding 5 years (20) . However, a recent study showed a decrease in BACs ≥50 mg/100 mL in fatally injured drivers following a reduction in BAC limit in Hong Kong (21) . Figure 4 shows area charts of the BAC data obtained in this study from (left) New Zealand and (right) Scotland. The charts represent the cumulative percentages of the BAC data, demonstrating how the BAC distribution in fatally injured drivers and motorcyclists has altered after the change in BAC limit for each country. From Fig. 4 (left) , it can be seen that in New Zealand, the proportion of fatally injured drivers and motorcyclists with high BACs appears to have increased. Before the BAC limit changẽ 50% of fatally injured drivers and motorcyclists had a BAC <100 mg/100 mL, following the change, only~30% of BACs were <100 mg/100 mL. It is possible that a 50 mg/100 mL limit does not have a particular impact on those people who tend, once they pass a certain initial BAC, to drink very heavily (6) . Due to the small numbers of MVC cases involving alcohol in Scotland, it is difficult to draw any further meaningful conclusions.
The difference in the profile of BAC results between the two jurisdictions may be due to differing social norms in the two countries about the acceptable amount of drinking before driving (23) . Reports in the U.K. media suggest that attitudes toward drink-driving in Scotland are overwhelmingly negative (45). In New Zealand, the NZTA reports that peer pressure and social drinking remain strong influences on drivers (42). Although high-profile campaigns about the change in BAC limit ran in both countries, researchers have noted that there is little evidence that mass communication campaigns significantly alter people's drinking and driving behavior (7). Another factor responsible for the differences in BAC distribution between the two countries may be differences in the prevalence of alcohol use disorders; previous work has suggested a link between drinking and driving with a BAC of 150 mg/100 mL and a clinical diagnosis of alcoholism (46) . Table 3 shows that~50% (range, 44-52%) of alcohol-positive drivers had a BAC ≥150 mg/100 mL in both countries before and after the BAC limit change. However, this does not appear to correlate with alcohol use disorder prevalence estimates for the two jurisdictions, as measured by the World Health Organisation, which were 1.52% (female) and 6.42% (male) in the U.K. (data for Scotland alone not available), and 2.20% (female) and 3.50% (male) in New Zealand (47).
Drugs
Drugs were categorized into "families" as previously described (48) . Table 4 shows the identity of the drugs in each family in this study. It should be noted that these results do not account for polydrug use (49) . Due to differences in the analyses undertaken by the two countries, not all blood drug concentrations were available. In cases where emergency medical treatment was indicated in the case records, findings of morphine, fentanyl, ketamine, midazolam, or lidocaine were excluded. Figure 5 shows a bar chart of the drug types detected in this study before and after the BAC limit change for both countries. A case was considered "positive" for a drug type if it contained one or more member(s) of that group, including metabolites. It should be noted that many of the drivers and motorcyclists from both countries were positive for more than one drug group. Figure 5 shows that cannabinoids were the most common drug finding in fatally injured drivers in New Zealand, whereas in Scotland, cannabinoids were overtaken by opioids after the BAC limit change. In New Zealand, the prevalence of cannabis use by fatally injured drivers increased over the 2-year period, although it appears to have remained constant in Scotland. Note that some of the cases from Scotland were positive only for carboxy-THC, an inactive metabolite of cannabis that can remain in the blood for some time after cannabis is used. Conversely, the prevalence of opioid use (mainly codeine) by fatally injured drivers has markedly increased in Scotland, while falling in New Zealand. In a recent survey of 2434 New Zealanders, the proportion of respondents driving after taking drugs was highest for opiates, followed by synthetic cannabis and cannabis (50) . A study of living drugged drivers in the U.K. reported cannabis as the most common finding (49); however, opioids may be more likely to be involved in fatalities than cannabis due to their pharmacological effects (51) .
Benzodiazepine prevalence increased in both jurisdictions, with diazepam being the most common benzodiazepine encountered in both datasets (all benzodiazepine-positive MVCs in Scotland contained diazepam). Clonazepam was found in five cases in New Zealand but was not seen in Scotland. As Table 4 demonstrates, this study does not include newer benzodiazepines such as diclazepam and etizolam.
There was only a small change in the prevalence of stimulant use by fatally injured drivers and motorcyclists in Scotland, and the prevalence in New Zealand remained steady over the 2-year period.
Other prescription drug use was recorded as being higher in fatally injured drivers in New Zealand compared to Scotland. This likely reflects differences in the screening approaches used by the two laboratories, including the instrumentation and analytical cutoffs applied (see Table S1 of the Supplementary Information). Prescription drug use is a particularly complex issue when assessing its involvement in impaired driving (52) , with some prescription drugs having no effect or resulting in driving improvement, and others causing significant impairment (53) . Those prescription drugs known to cause the greatest driving impairment (opioids and benzodiazepines) were placed in other drug families. Zopiclone was only detected in New Zealand and was considered part of the other prescription drug group, although unlike some of the drugs in that group, it is known to cause driving impairment (3) . Many of the prescription drugs detected were antidepressants; while some antidepressants are known to have a sedating effect (e.g., amitriptyline), it has also been shown that depressed individuals receiving long-term antidepressant treatment exhibit inferior driving skills compared to healthy controls (54) . The interpretation of prescription drugs found in fatally injured drivers is further complicated as it is often unknown whether substances were taken on prescription or recreationally (e.g., gabapentin) (52). Information on prescriptions was not available in every case, and drivers may also hold a valid prescription for a drug, but take more than directed.
The prevalence of over-the-counter drugs increased in Scotland over the 2-year period. All MVC cases containing over-thecounter drugs in Scotland before the BAC limit change and seven of the eight afterward were positive for paracetamol (78%). In New Zealand, 15 of the 18 MVC cases that were positive for over-the-counter drugs before (83%) and 14 of the 15 MVC cases afterwards (93%) contained paracetamol. In New Zealand and Scotland, five and three cases, respectively, that were positive for paracetamol were also positive for codeine, suggesting the use of codeine-paracetamol preparations, which are not known to cause impairment (55) . While over-the-counter drugs such as paracetamol and ibuprofen are not associated with driving impairment or increased crash risk, over-the-counter antihistamines such as diphenhydramine can significantly impair driving ability (56). Differences in the drug findings between the two countries could be due to differences in social attitudes to driving under the influence of drugs. In surveys of attitudes to drug driving in New Zealand (57) and Scotland (58), respondents from both jurisdictions perceived that their chances of being caught drug driving were lower than for drink-driving. Moreover, in Scotland, most people surveyed did not believe that their driving was adversely affected by drug use (58) .
Other drugs of abuse such as novel psychoactive substances (e.g., synthetic cannabinoids), hallucinogens (lysergic acid diethylamide, NBOMe compounds, etc.), inhalants, and gammahydroxybutyrate (GHB) were not part of routine toxicological testing in either country in this study.
Limitations
There are a number of important limitations to this study. First, it was not possible to account for other concomitant policies, variations in enforcement activities or public awareness, changes in other laws or trends in alcohol/drug consumption, and motor vehicle utilization that might affect the occurrence of, and toxicological findings in, traffic fatalities during the study period (11, 19) . Therefore, differences regarding the effect of the new legislation between the two regions studied may be explained by divergent police enforcement or other supporting measures, such as media coverage and preventive actions in each locality (19) or other factors we were not able to measure. There are a number of factors that affect drink-driving behavior, including increased perceived risk of prosecution; changes in behavior such as not drinking at all before driving, using a taxi, and an increase in designated sober drivers (6). Although we have attempted to minimize the effects of differing roadside testing policies by examining fatally injured drivers rather than impaired drivers, it is possible that such policies affected driver behavior during the period studied.
This study does not take into account culpability for MVCs or distinguish between single-and multiple-vehicle crashes; the presence of drugs and/or alcohol in fatally injured drivers therefore is not the same as a causal factor (59).
As mentioned above, assessing the impact of prescription and over-the-counter drugs on driving is complex. Risk profiles vary across drug classes and can vary within classes and even by drug, depending on dosage, duration of therapy, and underlying driver characteristics (60) . The use of such drugs may even improve driving, as there is strong evidence that unrelieved pain may decrease psychomotor and cognitive performance (55) . In addition, many of the deceased drivers in this study were positive for multiple substances, creating difficulty in determining whether or not certain drugs contributed to any impairment at the time of the MVC (52). We were also unable to assess the contribution of drug-drug interactions in polydrug use cases (61) , and there is the possibility that some drugs might have degraded in postmortem blood between sampling and testing (9) .
In terms of the alcohol findings, this study demonstrates that BACs at and around the legal BAC limits for New Zealand and Scotland do not represent the majority of fatal MVCs. The mean BACs measured (Table 3) were not within the 50-80 mg/ 100 mL range, either before or after the BAC limit change, and the numbers of BACs within the range 50-80 mg/100 mL were very small (<3) in both countries.
The extent to which our findings can be generalized to other countries may be limited by the small numbers of fatal MVCs recorded. There was also no control group unaffected by the reduced BAC limits; consequently, the observed changes in toxicological findings may not necessarily be a result of the legal amendments (23) . The dataset for Scotland is not complete, as it excludes the far Northern regions, and the small number of fatal MVCs in Scotland means that the trends observed around the change in BAC limit should be treated with caution. Finally, datasets from both countries did not include all fatal driver and motorcyclist MVCs during the period examined, due to some instructing authorities requesting only limited toxicological analyses or no autopsy being carried out.
Conclusion
This study has compared changes in the full toxicological findings in fatally injured drivers and motorcyclists in two jurisdictions, in the years before and after a change in the legal BAC limit for driving. In Scotland, there was an increase in cases positive for drugs, with the use of all drug groups increasing after the BAC limit change, with the exception of cannabinoids. In New Zealand, there was a reduction in cases involving drugs only, but increases in the numbers of deceased drivers and motorcyclists positive for alcohol only and co-using alcohol and drugs (cannabinoids, benzodiazepines, and other prescription drugs). In terms of the BAC findings, there was no statistically significant difference in mean BACs over the 2-year period for either country, and BACs at and around the legal limits did not represent the majority of fatal MVCs occurring. However, some differences in BAC distribution were observed: in New Zealand, there was an increase in the proportion of fatally injured drivers and motorcyclists with high BACs after the limit change. Due to FIG. 5--Breakdown of the drug types detected in blood samples from deceased drivers and motorcyclists in fatal MVCs before and after the BAC limit changes. For more information, see Table 4 . [Color figure can be viewed at wileyonlinelibrary.com] the small numbers of fatalities in Scotland, detailed conclusions could not be drawn.
Future work could examine data from both jurisdictions in later years following the BAC limit change, as studies have suggested that some effects wear off with time (16, 19) . The study could also be extended to include other fatally injured road users (e.g., passengers and pedestrians) or examine the impact of new drug-driving legislation involving drug limits to be introduced in Scotland in 2019.
